Business

• U.S. proposes critical minerals trade bloc aimed at countering China’s grip - The U.S. is mobilizing allies into a preferential trade bloc for critical minerals as part of efforts to counter China's dominance in the market.
• Sony profit jumps 22% in December quarter, beating expectations and lifting full-year outlook - TechSony profit jumps 22% in December quarter, beating expectations and lifting full-year outlookPublished Wed, Feb 4 202610:31 PM ESTDylan Butts@in/dylan-b-7a4
• Shares of Arm plunge 8% after licensing revenue misses estimates, Qualcomm outlook adds pressure - Shares of UK-based semiconductor designer Arm Holdings fell in aftermarket trading, despite the company posting record revenues amid AI demand.
• Qualcomm stock sinks as memory shortage drags on forecast - "We're starting to see that memory is going to define the size of the mobile market," Qualcomm CEO Cristiano Amon said in an interview.
• Uber reports 20% revenue growth in fourth-quarter, fueled by food delivery - Uber said revenue in its food delivery business increased 30%, beating analysts' estimates.
• Streaming-only Super Bowl ads give small brands a shot at the Big Game - The Super Bowl beckons some of the most expensive ads every year, and brands are finding a cheaper option in the streaming-only option.
• Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better - Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling. 
• AMD shares drop as forecast comes up short of some expectations - AMD's first-quarter forecast fell short of what some analysts were hoping for amid an AI spending boom.
• Chipotle stock sinks as restaurant chain reports falling traffic, weak guidance - Chipotle stock has fallen about 33% over the last year, dragging the company's market value down to about $51 billion.
• Novo Nordisk shares tumble after company warns of sales hit this year - The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.